335 related articles for article (PubMed ID: 36612258)
21. Review Article: Immune Landscape and Immunotherapy Options in Cervical Carcinoma.
Kousar K; Ahmad T; Naseer F; Kakar S; Anjum S
Cancers (Basel); 2022 Sep; 14(18):. PubMed ID: 36139618
[TBL] [Abstract][Full Text] [Related]
22. Safety and immunogenicity of TA-HPV, a recombinant vaccinia virus expressing modified human papillomavirus (HPV)-16 and HPV-18 E6 and E7 genes, in women with progressive cervical cancer.
Kaufmann AM; Stern PL; Rankin EM; Sommer H; Nuessler V; Schneider A; Adams M; Onon TS; Bauknecht T; Wagner U; Kroon K; Hickling J; Boswell CM; Stacey SN; Kitchener HC; Gillard J; Wanders J; Roberts JS; Zwierzina H
Clin Cancer Res; 2002 Dec; 8(12):3676-85. PubMed ID: 12473576
[TBL] [Abstract][Full Text] [Related]
23. Targeting of HPV-16+ Epithelial Cancer Cells by TCR Gene Engineered T Cells Directed against E6.
Draper LM; Kwong ML; Gros A; Stevanović S; Tran E; Kerkar S; Raffeld M; Rosenberg SA; Hinrichs CS
Clin Cancer Res; 2015 Oct; 21(19):4431-9. PubMed ID: 26429982
[TBL] [Abstract][Full Text] [Related]
24. Challenges and Prospects of Chimeric Antigen Receptor T-cell Therapy for Metastatic Prostate Cancer.
Gorchakov AA; Kulemzin SV; Kochneva GV; Taranin AV
Eur Urol; 2020 Mar; 77(3):299-308. PubMed ID: 31471138
[TBL] [Abstract][Full Text] [Related]
25. Anticancer traits of chimeric antigen receptors (CARs)-Natural Killer (NK) cells as novel approaches for melanoma treatment.
Bahmanyar M; Vakil MK; Al-Awsi GRL; Kouhpayeh SA; Mansoori Y; Mansoori B; Moravej A; Mazarzaei A; Ghasemian A
BMC Cancer; 2022 Nov; 22(1):1220. PubMed ID: 36434591
[TBL] [Abstract][Full Text] [Related]
26. Monoclonal antibodies in cervical malignancy-related HPV.
Aghbash PS; Hemmat N; Fathi H; Baghi HB
Front Oncol; 2022; 12():904790. PubMed ID: 36276117
[TBL] [Abstract][Full Text] [Related]
27. PD-1/PD-L1 inhibitors for advanced or metastatic cervical cancer: From bench to bed.
Huang W; Liu J; Xu K; Chen H; Bian C
Front Oncol; 2022; 12():849352. PubMed ID: 36313730
[TBL] [Abstract][Full Text] [Related]
28. Management of patients with recurrent/advanced cervical cancer beyond first line platinum regimens: Where do we stand? A literature review.
Boussios S; Seraj E; Zarkavelis G; Petrakis D; Kollas A; Kafantari A; Assi A; Tatsi K; Pavlidis N; Pentheroudakis G
Crit Rev Oncol Hematol; 2016 Dec; 108():164-174. PubMed ID: 27931835
[TBL] [Abstract][Full Text] [Related]
29. Role of Immune Checkpoint Inhibitors in Cervical Cancer: From Preclinical to Clinical Data.
Duranti S; Pietragalla A; Daniele G; Nero C; Ciccarone F; Scambia G; Lorusso D
Cancers (Basel); 2021 Apr; 13(9):. PubMed ID: 33925884
[TBL] [Abstract][Full Text] [Related]
30. Expanding Our Impact in Cervical Cancer Treatment: Novel Immunotherapies, Radiation Innovations, and Consideration of Rare Histologies.
Randall LM; Walker AJ; Jia AY; Miller DT; Zamarin D
Am Soc Clin Oncol Educ Book; 2021 Mar; 41():252-263. PubMed ID: 34010052
[TBL] [Abstract][Full Text] [Related]
31. Immune responses against virus and tumor in cervical carcinogenesis: treatment strategies for avoiding the HPV-induced immune escape.
Conesa-Zamora P
Gynecol Oncol; 2013 Nov; 131(2):480-8. PubMed ID: 23994536
[TBL] [Abstract][Full Text] [Related]
32. Development of a TCR-like antibody and chimeric antigen receptor against NY-ESO-1/HLA-A2 for cancer immunotherapy.
Liu X; Xu Y; Xiong W; Yin B; Huang Y; Chu J; Xing C; Qian C; Du Y; Duan T; Wang HY; Zhang N; Yu JS; An Z; Wang R
J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35338087
[TBL] [Abstract][Full Text] [Related]
33. The potential applications of T cell receptor (TCR)-like antibody in cervical cancer immunotherapy.
Dass SA; Selva Rajan R; Tye GJ; Balakrishnan V
Hum Vaccin Immunother; 2021 Sep; 17(9):2981-2994. PubMed ID: 33989511
[TBL] [Abstract][Full Text] [Related]
34. Cervical cancer therapies: Current challenges and future perspectives.
Burmeister CA; Khan SF; Schäfer G; Mbatani N; Adams T; Moodley J; Prince S
Tumour Virus Res; 2022 Jun; 13():200238. PubMed ID: 35460940
[TBL] [Abstract][Full Text] [Related]
35. MVA E2 recombinant vaccine in the treatment of human papillomavirus infection in men presenting intraurethral flat condyloma: a phase I/II study.
Albarran Y Carvajal A; de la Garza A; Cruz Quiroz BJ; Vazquez Zea E; Díaz Estrada I; Mendez Fuentez E; López Contreras M; Andrade-Manzano A; Padilla S; Varela AR; Rosales R
BioDrugs; 2007; 21(1):47-59. PubMed ID: 17263589
[TBL] [Abstract][Full Text] [Related]
36. Recent developments in immunotherapy of cancers caused by human papillomaviruses.
Fakhr E; Modic Ž; Cid-Arregui A
Immunology; 2021 May; 163(1):33-45. PubMed ID: 33205441
[TBL] [Abstract][Full Text] [Related]
37. Combinatorial approaches to effective therapy in glioblastoma (GBM): Current status and what the future holds.
Asija S; Chatterjee A; Yadav S; Chekuri G; Karulkar A; Jaiswal AK; Goda JS; Purwar R
Int Rev Immunol; 2022; 41(6):582-605. PubMed ID: 35938932
[TBL] [Abstract][Full Text] [Related]
38. Paving the road to make chimeric antigen receptor-T-cell therapy effective against solid tumors.
Adachi K; Tamada K
Cancer Sci; 2022 Dec; 113(12):4020-4029. PubMed ID: 36047968
[TBL] [Abstract][Full Text] [Related]
39. Genetically Modified T-Cell-Based Adoptive Immunotherapy in Hematological Malignancies.
Ye B; Stary CM; Gao Q; Wang Q; Zeng Z; Jian Z; Gu L; Xiong X
J Immunol Res; 2017; 2017():5210459. PubMed ID: 28116322
[TBL] [Abstract][Full Text] [Related]
40. HPV: Molecular pathways and targets.
Gupta S; Kumar P; Das BC
Curr Probl Cancer; 2018; 42(2):161-174. PubMed ID: 29706467
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
